Journal
ONCOGENE
Volume 41, Issue 23, Pages 3177-3185Publisher
SPRINGERNATURE
DOI: 10.1038/s41388-022-02329-3
Keywords
-
Funding
- CPRIT [RP160710/RP170172]
- NIH/NCI [R01CA200970/2R01CA155243]
- NSF [PHY-1935762]
- Bowes Foundation
- MD Anderson Cancer Center Support Grant [CA016672]
Ask authors/readers for more resources
Therapeutic resistance and metastatic progression are the main causes of cancer deaths, with cancer stem cells (CSCs) playing a crucial role in these processes. p38 MAPK is important for CSC development and maintenance, and its targeting can enhance chemotherapy sensitivity and prevent metastatic progression.
Therapeutic resistance and metastatic progression are responsible for the majority of cancer mortalities. In particular, the development of resistance is a significant barrier to the efficacy of cancer treatments such as chemotherapy, radiotherapy, targeted therapies, and immunotherapies. Cancer stem cells (CSCs) underlie treatment resistance and metastasis. p38 mitogen-activated protein kinase (p38 MAPK) is downstream of several CSC-specific signaling pathways, and it plays an important role in CSC development and maintenance and contributes to metastasis and chemoresistance. Therefore, the development of therapeutic approaches targeting p38 can sensitize tumors to chemotherapy and prevent metastatic progression.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available